This is a list of papers funded by Cure Alzheimer’s Fund. It also includes “layperson” descriptions of each paper. We are grateful to the researchers for translating the work of their papers into language more accessible to most of us than the more precise technical language useful to them and ...
August 20, 2009
2019 Neuritic plaques surround amyloid deposits and are made up of swollen, dystrophic neural processes that contain aggregated phosphorylated tau. Neurofibrillary tangles are made up of phosphorylated tau that has abnormally been aggregated in Alzheimer’s disease. Tau normally is microtubule adaptor protein involved in the highways of neurons that allow for ...
January 11, 2016
The Alzheimer’s Study Group was established on July 11, 2007 under the auspices of the Congressional Task Force on Alzheimer’s Disease with the charge of creating a National Alzheimer’s Strategic Plan to overcome America’s mounting Alzheimer’s crisis. The National Alzheimer’s Strategic Plan was released at a hearing before the U.S. Senate ...
March 26, 2009
As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s ...
March 23, 2015
Annual Awards Support “Tomorrow’s Leaders in Alzheimer’s Disease Research;” Honor Legacies of Drs. George Glenner and Leon Thal April 9, 2008 – A coalition of leading Alzheimer’s disease organizations today announced the first three recipients of “Tomorrow’s Leaders in Alzheimer’s Disease Research” prizes; a new award mechanism to recognize outstanding young scientists ...
April 15, 2009
January 30, 2024
Setting the stage The 10th Annual International Conference on Alzheimer’s Disease/Parkinson’s Disease (AD/PD) was held this March in Barcelona with thousands of researchers from 68 countries attending. Chief among the topics of interest was determining risk for the disease from genetics. The useful source for all things Alzheimer’s, The Alzheimer’s Research ...
April 7, 2011
2024 The Alzheimer’s Genome Project™ (AGP) is aimed at identifying and characterizing novel Alzheimer’s disease (AD) genes using an extensive genetic database consisting of our own collaborative and all publicly available AD genome-wide association study (GWAS), whole genome sequence (WGS) and whole exome sequence (WES) data. In the AGP, we use ...
January 9, 2020
October 15, 2019
(Distributed by Amylyx Pharmaceuticals on June 15, 2020) Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced it has completed enrollment in the Phase II PEGASUS trial assessing AMX0035 in individuals with Alzheimer’s disease. Amylyx completed ...
October 23, 2020
